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BACKGROUND: Exposure to perﬂuoroalkyl substances (PFASs) may increase risk for metabolic diseases; however, epidemiologic evidence is lacking
at the present time. Pregnancy is a period of enhanced tissue plasticity for the fetus and the mother and may be a critical window of PFAS exposure
susceptibility.
OBJECTIVE:We evaluated the associations between PFAS exposures and metabolic outcomes in pregnant women.
METHODS: We analyzed 1,240 pregnant women from the Spanish INMA [Environment and Childhood Project (INfancia y Medio Ambiente)] birth
cohort study (recruitment period: 2003–2008) with measured ﬁrst pregnancy trimester plasma concentrations of four PFASs (in nanograms/milliliter).
We used logistic regression models to estimate associations of PFASs (log10-transformed and categorized into quartiles) with impaired glucose toler-
ance (IGT) and gestational diabetes mellitus (GDM), and we used linear regression models to estimate associations with ﬁrst-trimester serum levels
of triglycerides, total cholesterol, and C-reactive protein (CRP).
RESULTS: Perﬂuorooctane sulfonate (PFOS) and perﬂuorohexane sulfonate (PFHxS) were positively associated with IGT (137 cases) [OR per
log10-unit increase= 1:99 (95% CI: 1.06, 3.78) and OR=1:65 ( 95% CI: 0.99, 2.76), respectively]. PFOS and PFHxS associations with GDM (53
cases) were in a similar direction, but less precise. PFOS and perﬂuorononanoate (PFNA) were negatively associated with triglyceride levels [percent
median change per log10-unit increase= − 5:86% (95% CI: −9:91%, − 1:63%) and percent median change per log10-unit increase= − 4:75% (95%
CI: − 8:16%, − 0:61%, respectively], whereas perﬂuorooctanoate (PFOA) was positively associated with total cholesterol [percent median change
per log10-unit increase= 1:26% (95% CI: 0.01%, 2.54%)]. PFASs were not associated with CRP in the subset of the population with available data
(n=640).
CONCLUSIONS: Although further conﬁrmation is required, the ﬁndings from this study suggest that PFAS exposures during pregnancy may inﬂuence
lipid metabolism and glucose tolerance and thus may impact the health of the mother and her child. https://doi.org/10.1289/EHP1062
Introduction
Perﬂuoroalkyl substances (PFASs) have been used in many appli-
cations since the 1950s, including industrial applications and con-
sumer products (Casals-Casas and Desvergne 2011). PFASs
bioaccumulate in the food chain and in animal and human tissues,
and exposure persists in the environment and living organisms
for years (Wang et al. 2014). The routes of human exposure to
PFASs include diet (animal and plant-based foods), migration
from packaged foods, drinking water, and inhalation of indoor
dust (Wang et al. 2014). Detectable blood levels of PFASs have
been reported in pregnant women in Spain (Manzano-Salgado
et al. 2015) and in other European (Gebbink et al. 2015), North
American (Kato et al. 2014), Asian (Okada et al. 2013), and
African (Hanssen et al. 2010) regions. PFAS exposure may pass
from mother to child through the placenta (Manzano-Salgado
et al. 2015) and through breast milk (Mogensen et al. 2015).
Evidence from epidemiological studies suggests that expo-
sures to PFASs and to other endocrine-disrupting chemicals
(EDCs) (i.e., synthetic substances that have been shown to alter
the function of the endocrine system in intact organisms) may
contribute to obesity (de Cock and van de Bor 2014), lipid altera-
tions (Kabir et al. 2015), diabetes (Taylor et al. 2013), and to
autoimmune diseases and inﬂammation (Kuo et al. 2012). A
study of female CD-1 mice reported that mice exposed to low
doses of perﬂuorooctanoate (PFOA) in utero had higher serum
insulin and leptin concentrations at 21–33 wk of age than controls
(Hines et al. 2009). Rats exposed to PFOA or perﬂuorooctane
sulfonate (PFOS) were reported to have lower total serum choles-
terol levels and to show evidence of liver toxicity compared with
controls (Lau et al. 2007). Experimental evidence further sup-
ports that PFOA and PFOS exposures may alter inﬂammatory
responses and the production of cytokines (DeWitt et al. 2012)
that play a role in the pathogenesis of metabolic diseases (Caër
et al. 2017).
Few epidemiological studies have evaluated associations bet-
ween PFAS exposures and metabolic outcomes, and ﬁndings
have been inconclusive. A cross-sectional study of 571 adults in
Taiwan reported that PFOS was positively associated with preva-
lent diabetes, but associations with other PFAS compounds were
negative (inverse) (Su et al. 2016). A prospective cohort study of
258 pregnant women in the United States reported a positive
association between serum PFOA concentrations and gestational
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diabetes mellitus (GDM); associations of other PFASs were posi-
tive but close to the null (Zhang et al. 2015). However, a prospec-
tive study of 1,274 pregnant women in Canada reported limited
evidence of a positive association with GDM for plasma perﬂuor-
ohexane sulfonate (PFHxS) (signiﬁcant for the second vs. ﬁrst
quartile comparison only) and no evidence of associations for
PFOA or PFOS (Shapiro et al. 2016). Similarly, a recent study of
604 pregnant Faroese women that used a multiple-pollutant mod-
eling approach found no association of PFAS exposures with
GDM (Valvi et al. 2017). Further, a Norwegian study of PFASs
and serum lipid levels in second-trimester samples from 891
pregnant women reported that PFOS was positively associated
with total cholesterol, low-density lipoprotein (LDL), and high-
density lipoprotein (HDL), and that PFOA, PFHxS, and three
other PFASs were also positively associated with HDL (Starling
et al. 2014). Finally, a Danish study that examined PFOS, PFOA,
and total cholesterol in serum samples collected from 854 women
during the 30th week of gestation reported positive associations
for both PFASs (Skuladottir et al. 2015).
Exposure during pregnancy may aﬀect the mother and may
also aﬀect her child during gestation and in later life (Bach et al.
2015; Casals-Casas and Desvergne 2011). However, until now,
only a few studies with relatively small populations have exam-
ined the potential role of PFAS exposures on metabolic outcomes
at pregnancy (Starling et al. 2014; Skuladottir et al. 2015; Zhang
et al. 2015). Therefore, we evaluated associations of exposures in
early pregnancy to PFOS, PFOA, and the emerging PFAS com-
pounds PFHxS and PFNA with metabolic outcomes including
impaired glucose tolerance (IGT) and GDM, and with serum lev-
els of triglycerides, total cholesterol, and C-reactive protein
(CRP), in a cohort of Spanish women.
Methods
Study Population and Data Collection
The population-based birth cohort study INMA [INfancia y
Medio Ambiente (Environment and Childhood)] recruited 2,150
pregnant women in the Spanish regions of Valencia (n=855),
Sabadell (n=657), and Gipuzkoa (n=638) between 2003 and
2008 (Guxens et al. 2012). Women were enrolled during the ﬁrst
trimester of pregnancy at the primary health care center or hospi-
tal of each region and afterwards were followed at the third tri-
mester of pregnancy and at birth. The inclusion criteria were
≥16 years of age, no assisted reproduction, a singleton preg-
nancy, intention to deliver at the reference hospital, and no com-
munication handicap. Because the main focus of the INMA
studies is on child health, plasma PFAS analysis was limited to
mother–child pairs who had archived plasma samples from preg-
nancy and information on child health outcomes at 4 y of age
(n=1,243). Of these, 1,240 mothers who also had information
about at least one of the metabolic outcomes of interest were
included in the present analysis (58% of those initially enrolled)
(see Figure S1). Investigators who performed the PFAS analyses
did not have information on the women’s metabolic outcomes,
and those who assessed the metabolic outcomes did not have in-
formation on PFAS concentrations. To assess potential selection
bias, we performed a comparison of main characteristics between
pregnant women included in and excluded from analysis.
Nonfasting blood samples were collected from the women at
the ﬁrst-trimester prenatal visit, and interview-based question-
naires administered by trained research staﬀ were used to collect
information about sociodemographic (including age, education,
occupation, and parity history) and lifestyle characteristics
(including alcohol consumption and smoking during pregnancy)
at ﬁrst- and third-trimester prenatal visits.
All participants provided written informed consent. The study
was approved by the hospital ethics committees of each partici-
pating region.
Exposure Assessment of PFAS
Plasma was separated from blood samples collected at approxi-
mately 13 wk of gestation (13:1±1:4), aliquoted into 1:5-mL
cryotubes, and stored at −80C until analysis at the Institute for
Occupational Medicine, Rheinisch-Westfälische Technische
Hochschule (RWTH) Aachen University, Germany, as previ-
ously described (Manzano-Salgado et al. 2015). Plasma con-
centrations of PFASs were determined using column-switching
high performance liquid chromatography (HPLC) (Agilent
1100 Series HPLC) coupled to tandem mass spectrometry
(Sciex API 3000 LC/MS/MS System). The limit of quantiﬁca-
tion (LOQ) was 0:20 ng=mL for PFOS, PFOA, and PFHxS, and
0:10 ng=mL for PFNA.
Metabolic Outcomes
In Spain, the routine clinical examination for GDM in pregnant
women is performed at 24–28 wk of gestation according to the
guidelines recommended by the Spanish Group of Diabetes and
Pregnancy. Women whose physicians considered them to be at
high risk for GDM [based on age, body mass index (BMI),
personal/family history of diabetes, or previous pregnancy compli-
cations] were given a 50-g oral glucose challenge test (OGCT),
with blood glucose values measured after 1 h. Women with a post-
challenge blood glucose ≥140 mg=dL on the OGCT completed a
100-g 3-h oral glucose tolerance test (OGTT) 2–3 wk after the ﬁrst
screening test, with blood glucose concentrations measured at base-
line and 1, 2, and 3 h after the glucose challenge. Results of the
OGTT are routinely used to classify women as having GDM if two
or more of the baseline or postchallenge blood glucose concentra-
tions exceed National Diabetes Data Group (NDDG) reference val-
ues (Expert Committee on the Diagnosis and Classiﬁcation of
Diabetes Mellitus 2003) and as having IGT only (without GDM) if
one or fewer of the four blood glucose concentrations exceeds
NDDG reference values. We extracted information about IGT and
GDM diagnosis from the medical records. Information about GDM
was available for women from all three INMA subcohorts, but in-
formation about IGT only (i.e., IGT in women not diagnosed with
GDM) was available in the medical records for women in the
Sabadell and Gipuzkoa cohorts. Our a priori hypothesis was that
PFAS exposures may interfere with insulin signaling, glucose ho-
meostasis, or both (Yan et al. 2015, Qiu et al. 2016), which could
result in elevated blood glucose levels as well as in GDM.
Therefore, we used one set of logistic regression models to estimate
associations between PFASs and GDM (with noncases deﬁned as
all women without a diagnosis of GDM, regardless of whether they
had IGT), and a second set of models to estimate associations
between PFASs and IGT, where all women diagnosed with GDM
or IGT were classiﬁed as cases, and all remaining women were
classiﬁed as noncases. In addition, we performed a sensitivity anal-
ysis in which we repeated the logistic regression models of associa-
tions with IGT after excluding women from the Valencia
subcohort because Valencia women with IGT but not GDM would
have been misclassiﬁed as noncases owing to missing IGT
information.
Total cholesterol and triglycerides were determined in mater-
nal nonfasting serum collected at approximately 13 wk of gesta-
tion using colorimetric enzymatic methods. Measurements were
performed at the Bizkaia Basque Country Public Health
Laboratory for the Gipuzkoa and Sabadell subcohorts and at the
General Biochemistry Laboratory of La Fe Hospital (Valencia)
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for the Valencia subcohort. CRP levels were measured in ﬁrst-
trimester pregnancy serum by immunoturbidimetry at the
Consulting Químico Sanitario (CQS) Laboratory for the Gipuzkoa
subcohort and at the Echevarne Sabadell Laboratory for the
Sabadell subcohort. CRP levels were not measured in the Valencia
subcohort.
Other Covariates
We considered a wide range of potential confounders based on
previous literature related to PFAS exposures (Berg et al. 2014;
Manzano-Salgado et al. 2016; Sagiv et al. 2015) and/or metabolic
outcomes in pregnant women (Halldorsson et al. 2012; Perng
et al. 2014; Ryckman et al. 2015; Skuladottir et al. 2015; Starling
et al. 2014; Taylor et al. 2013; Wild et al. 2015; Zhang et al.
2015). These confounders included subcohort (Valencia, Sabadell,
Gipuzkoa), country of birth, age, gestational week at blood extrac-
tion, parity, previous breastfeeding duration, marital status (living
with the child’s father, other situation), education, social class
[based on occupation according to the International Standard
Classiﬁcation of Occupations–88: I and II, professionals and man-
agers; III, other nonmanual and skilled; IV and V, semiskilled and
unskilled manual (http://www.ilo.org/public/english/bureau/stat/
isco/isco88/index.htm)], occupation at ﬁrst prenatal visit, smoking
during pregnancy, physical activity [in metabolic equivalents of
task (METs) per hour per day], and prepregnancy BMI (kilograms/
meters squared; based on prepregnancy self-reported weight di-
vided bymeasured squared height at ﬁrst prenatal visit).We further
considered the potential confounding role of the women’s diet in
the past three months before the blood extraction for PFAS analy-
sis; this was assessed at the ﬁrst prenatal visit using a 101-item
food frequency questionnaire (FFQ) previously validated in
Spanish adults (Vioque et al. 2013). From the FFQ,we obtained in-
formation on total energy (kilocalories/day), alcohol (grams/day),
ﬁsh and red meat intake (categorized in tertiles by servings/week),
and the relative Mediterranean Diet Score (rMED), a proxy mea-
sure of diet quality based on the extent of adherence to a
Mediterranean diet (Fernández-Barrés et al. 2016).
Statistical Analysis
We substituted maternal PFAS concentration values that were
below the LOQ with LOQ/4. We calculated the Spearman correla-
tion coeﬃcients between PFASs. PFAS concentrations, triglycer-
ides, and CRP levels had right-skewed distributions and therefore
were log10-transformed.
We used generalized additive models (GAMs) to examine
the linearity of the relationships between continuous log10-
transformed PFAS concentrations and the metabolic outcomes.
Because some of the associations were not linear (i.e., a p-
gain in the GAM <0:10; see Table S1), we show eﬀect esti-
mates for both continuous PFASs and per quartile of PFAS
exposure. We used logistic regression to estimate associations
between log10-transformed PFAS concentrations and dichoto-
mous outcomes (i.e., IGT and GDM), and we used linear
regression models to estimate associations with continuous
outcomes (serum cholesterol, log10-transformed triglycerides,
and log10-transformed CRP concentrations). We estimated all
associations using a basic model adjusted for subcohort only
and using a fully adjusted model with additional covariates.
We tested for heterogeneity among subcohorts by including
an interaction term (PFAS× subcohort) in the fully adjusted
models (data not shown). All interaction terms were nonsigni-
ﬁcant (p>0:10); therefore, we report coeﬃcients from analy-
ses of the overall population only.
The analysis population included 1,240 women with informa-
tion about GDM/IGT and 1,194 women with information about
serum lipid levels (see Figure S1). Analyses of associations with
serum CRP levels were limited to 651 women from the Sabadell
and Gipuzkoa subcohorts because CRP was not measured in the
Valencia subcohort. The fully adjusted models included slightly
fewer observations owing to missing data for additional covari-
ates (≤2%). Because of the low proportion of observations with
missing covariate data, we performed complete case analyses.
Covariates included in the multivariable-adjusted models
were selected using directed acyclic graphs (DAGs, data not
shown) including subcohort, women’s country of birth, previous
breastfeeding, parity history, prepregnancy BMI, and gestational
week at blood collection. Other potential confounders were eval-
uated and retained if adjustment caused a >10% change in eﬀect
estimates for PFASs and the study outcomes; thus, the fully
adjusted models also included physical activity and rMED.
We performed sensitivity analyses of associations between
PFASs and IGT after excluding women from the Valencia subco-
hort (because of missing information about their IGT status). In
addition, we estimated associations with all metabolic outcomes
using multiple-pollutant models adjusted simultaneously for all
four PFAS compounds.
To facilitate the interpretation of eﬀect estimates for continu-
ous outcomes, coeﬃcients are expressed as relative percent
change in medians (Barrera-Gómez and Basagaña 2015). The
level of statistical signiﬁcance was set to a two-sided p-
value<0:05. All analyses were conducted using STATA statisti-
cal software (version 12.0; StataCorp LLC).
Results
Study Population Characteristics
Nearly all of the women were born in Spain (93.2%), and most
were working during the ﬁrst pregnancy trimester (73.6%);
approximately half were of lower social class (IV–V: 46.9%) and
nulliparous (56.1%) (Table 1). Most women had never breastfed
(60.7%) and did not report smoking during pregnancy (68.6%),
and 18.5% and 7.9% were classiﬁed as overweight and obese,
respectively, based on their BMI before pregnancy (Table 1).
Compared with women excluded from the present analysis, those
who were included were slightly older (mean age 31.9 y vs. 31.4
y) and were more likely to be born in Spain (93.2% versus
86.5%), to have a university education (35.1% versus 29.2%), to
be of higher social class (Class I–II: 24% vs. 17%), and to have
lower average total energy intake (2086 kcal=day vs. 2202 kcal=
day) (Table 1).
The overall prevalences of GDM and IGT (including GDM
cases) were 4.3% and 11%, respectively (Table 2). The INMA-
Sabadell subcohort had the highest prevalence of IGT (17%), and
the INMA-Valencia subcohort had the highest prevalence of
GDM (5.3%). INMA study participants who were excluded from
the present analysis were less likely to be diagnosed with GDM
(2.6%) or IGT (6.6%) than women who were included. Compared
with women who were excluded, women included in the present
analysis had similar mean cholesterol (195±33 mg=dL vs. 196±
35 mg=dL) and geometric mean CRP concentrations (0:4± 2:4
for both groups), but slightly lower geometric mean triglycer-
ide concentrations (98:1± 1:5 mg=dL vs. 101:7± 1:5 mg=dL,
p=0:04). Women from the INMA-Valencia subcohort had
higher average cholesterol and triglycerides than women from
the other two cohorts (Table 3).
PFOS and PFOA concentrations were quantiﬁed in all sam-
ples analyzed, and PFHxS and PFNA concentrations were below
the LOQ in 3.7% and 0.65% of samples, respectively (Table 4).
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PFOS had the highest geometric mean concentration, followed
by PFOA, PFNA, and PFHxS. PFOA and PFNA were the most
highly correlated PFASs (Spearman’s rho= 0:68), followed by
PFOA and PFHxS (rho= 0:55). For other pairs of PFASs, the
correlation coeﬃcients ranged from 0.44 to 0.52.
Associations between PFAS Exposures and Metabolic
Outcomes
Association estimates from basic and fully adjusted models were
generally consistent, with a nonsigniﬁcant positive association
between PFOS and GDM [n=53 cases; adjusted OR for a 1-unit
increase in log10-PFOS=2:40 (95% CI: 0.93, 6.18)], without a
clear monotonic dose–response trend (Table 5 and Figure 1A).
PFHxS was also positively associated with GDM, although ORs
were closer to the null and were not signiﬁcant. ORs for IGT
(n=137 cases) were more precise, with a positive association
with PFOS [OR for a 1-unit increase in log10-PFOS=1:99 (95%
CI: 1.06, 3.78)] that was similar for all quartiles relative to the
lowest quartile (Table 5 and Figure 1B). As for GDM, PFHxS
was also positively associated with IGT, although ORs were
closer to the null than for PFOS. Associations between PFASs
and IGT were generally consistent with the main analyses when
women from the Valencia cohort were excluded, although the
Table 1. Characteristics of pregnant women included and excluded from the analysis.
Characteristic
Included (n=1,240)a Excluded (n=910)a
p-Valuebn Mean±SD or % n Mean±SD or %
Sociodemographic factors
Subcohort
Gipuzkoa 322 25.9% 316 34.7% <0:01
Sabadell 411 33.1% 246 27.1%
Valencia 507 40.9% 348 38.2%
Country of birth
Spanish 1,151 93.2% 761 86.5% <0:01
Others 84 6.8% 119 13.5%
Missing 5 0.4% 30 3.3%
Maternal age (y) 1,237 31:9± 4 695 31:4± 4:5 0.04
Missing 3 0.2% 215 24%
Parity
Nulliparous 695 56.1% 473 53.7% 0.28
Multiparous 543 43.9% 407 46.3%
Missing 2 0.2% 66 7.2%
Breastfeeding history
None 751 60.7% 531 60.3% 0.46
0–6 months 213 17.1% 156 17.8%
>6months 274 22.2% 193 21.9%
Missing 2 0.2% 30 3.2%
Education
Primary education or less 282 22.8% 281 31.9% <0:01
Secondary education 521 42.1% 341 38.8%
University degree 434 35.1% 257 29.2%
Missing 3 0.2% 31 3.4%
Social class
I–II: Professionals and managers 297 23.9% 150 17% <0:01
III: Skilled manual/nonmanual 361 29.1% 207 23.5%
IV–V: Semiskilled/unskilled 582 46.9% 525 59.5%
Lifestyle factors
Pre-BMI (kg=m2)c
Underweight 54 4.3% 47 5.4% 0.63
Normal 858 69.2% 615 69.9%
Overweight 229 18.5% 152 17.3%
Obese 99 7.9% 65 7.4%
Smoking during pregnancy
Never smoked 841 68.6% 507 65.6% 0.35
Smoked until 1st trimester 187 15.2% 125 16.2%
Smoked until 3rd trimester 198 16.1% 141 18.2%
Missing 14 1.1% 137 15%
Alcohol intake at 1st trimester [GM (GSD)] 1,234 0.3 (5.2) 900 0.3 (4.8) 0.27
Missing 6 0.5% 10 1.1%
Physical activity during 1st trimester (METs/hour/day) 1,235 37:7± 3:7 866 38:1± 3:7 0.97
Missing 5 0.4% 44 4.8%
Relative Mediterranean diet score
Low 389 31.7% 281 32.9% 0.97
Middle 551 44.9% 376 44.1%
High 286 23.3% 197 23.1%
Missing 14 1.1% 56 6.1%
Total energy intake (kcal/day) 1,234 2086± 514 869 2202± 640 <0:01
Missing 6 0.5% 41 4.5%
Note: BMI, body mass index; GM, geometric mean; GSD, geometric standard deviation; MET, metabolic equivalent of task; SD, standard deviation.
aSome covariates include fewer observations because of missing values.
bp-Value for the comparison between participants included and not included in analysis; Chi-squared test for percentage values comparisons and Student’s t-test for media values
comparisons.
cClassification according to World Health Organization (WHO) criteria.
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estimates were less precise (n=719 observations and 108 cases
only) (Table 5). All four PFASs were negatively associated with
serum triglyceride concentrations, although associations were
close to the null for PFOA and somewhat stronger for PFOS [per-
cent change in the median per unit increase in log10-PFOS=
− 5:86% (95% CI: − 9:91, − 1:63%)] and PFNA [percent change
per unit increase in log10-PFNA= − 4:75% (95% CI: − 8:16,
− 0:61%)] than for PFHxS, and estimated associations were simi-
lar for all quartiles relative to the lowest quartile (Table 6 and
Figure 2A). Associations between PFASs and triglycerides were
nonlinear for PFHxS and PFNA (see Table S1). Serum choles-
terol levels were positively associated with PFOA [percent
change in median per unit increase in log10-PFOA=1:26%
(95% CI: 0.01, 2.54%)], with similar eﬀect estimates for all
quartiles (Table 6 and Figure 2B). However, associations
between total cholesterol and the other PFASs were essentially
null. Associations between PFASs and CRP were based on only
640 observations (because of missing CRP data for Valencia
women), and the results were imprecise and inconclusive (Table
6 and Figure 2C).
Sensitivity Analyses
In the multivariate-adjusted models including all four PFAS com-
pounds, associations with the odds for GDM and IGT were
strengthened for PFOS and attenuated for PFHxS (see Table S2).
Further, the positive association between PFOA and serum total
cholesterol levels increased in magnitude [percent change in me-
dian per unit increase in log10-PFOA=2:04% (95% CI: 0.20,
3.93%)], whereas associations of PFOS and PFNA with triglycer-
ide levels were attenuated (see Table S3).
Discussion
Findings from this large study provide evidence for associa-
tions between PFAS exposures and metabolic outcomes in
pregnant women. Plasma PFOS concentrations were positively
associated with both IGT and GDM, although estimates for
GDM were based on fewer cases and were less precise, and
ORs were comparable for all quartiles relative to the lowest
exposure category. PFHxS was also positively associated with
both outcomes, although ORs were closer to the null than
those for PFOS. Further, PFOA concentrations were associated
with a slight increase in nonfasting serum cholesterol levels,
whereas PFOS and PFNA concentrations were associated with
small decreases in serum triglyceride levels. In multipollutant
models adjusted for all PFAS compounds, the associations
between PFOS concentrations and the odds for IGT or GDM
and those between PFOA and cholesterol levels were strength-
ened, whereas associations for PFHxS and PFNA with the
study outcomes were attenuated. Moreover, we did not ﬁnd
evidence for associations between PFAS exposures and serum
CRP levels, although this analysis was based on only a subset
of the study population (n=640), which may in part explain
the imprecise coeﬃcients.
To our knowledge, only three previous epidemiologic studies,
with median concentrations of PFOS, PFOA, or both that were
two to three times as high as those in our population, have eval-
uated the associations between PFAS concentrations and risk for
GDM. In a prospective cohort study of 258 U.S. women, PFOA
concentrations were signiﬁcantly associated with self-reported
GDM, whereas ORs for PFOS, PFNA, and four additional
PFASs were close to the null (Zhang et al. 2015). In a prospective
study of Canadian women, PFHxS was positively associated
with IGT (49 cases vs. 1,102 women with normal blood glu-
cose), but the association was nonlinear and was strongest for
the second versus ﬁrst quartile (Shapiro et al. 2016). In
Table 2. Prevalence [n(%)] of gestational diabetes mellitus and impaired glucose tolerance in pregnant women from the INMA birth cohort study.
Prevalence status All INMA subcohorts INMA-Valencia INMA-Sabadell INMA-Gipuzkoa
Women excluded from analysis
(all INMA subcohorts) p-Valuea
GDM
No 1,187 (95.7) 480 (94.7) 397 (96.6) 310 (96.3) 886 (97.4) 0.05
Yes 53 (4.3) 27 (5.3) 14 (3.4) 12 (3.7) 24 (2.6)
IGTb
No 1,103 (88.9) 480 (94.7)c 323 (83.0) 300 (87.2) 850 (93.4) 0.02
Yes 137 (11.1) 27 (5.3)c 66 (17.0) 44 (12.8) 60 (6.6)
Note: GDM, gestational diabetes mellitus; IGT, impaired glucose tolerance; INMA, Environment and Childhood Project (INfancia y Medio Ambiente).
aChi-squared test p-value comparing prevalences between participants included and excluded from analysis.
bCases include women diagnosed with GDM (all subcohorts) and women diagnosed with IGT (Sabadell and Gipuzkoa subcohorts only).
cIGT cases and noncases in the Valencia cohort are classified based on GDM only because IGT data were not available for this subcohort.
Table 4. Plasma PFAS concentrations (nanograms/milliliter) in pregnant
women participating in the INMA birth cohort study (n=1,240).
PFAS
n<LOQa
(%) GM (GSD) Min
Percentiles
Max5th 25th 50th 75th 95th
PFOA 0 2.31 (1.71) 0.28 0.96 1.63 2.35 3.30 5.23 31.64
PFOS 0 5.77 (1.61) 0.28 2.52 4.51 6.05 7.81 11.35 38.58
PFHxS 46 (3.71) 0.55 (1.96) 0.05 0.24 0.40 0.58 0.82 1.39 11.00
PFNA 8 (0.65) 0.64 (1.75) 0.03 0.28 0.49 0.65 0.90 1.49 5.51
Note: GM, geometric mean; GSD, geometric standard deviation; INMA, Environment
and Childhood Project (INfancia y Medio Ambiente); LOQ, limit of quantification;
Max, maximum value; Min, minimum value; PFAS, perfluoroalkyl substance; PFHxS,
perfluorohexane sulfonate; PFNA, perfluorononanoate; PFOA, perfluorooctanoate;
PFOS, perfluorooctane sulfonate.
aThe LOQ was 0:20 ng=mL for PFHxS, PFOS, PFOA and 0:10 ng=mL for PFNA.
Table 3. Serum lipids and C-reactive protein in pregnant women from the
INMA birth cohort study.
Serum lipid/protein levels n Min–Max Mean (SD) P25 P50 P75
Cholesterol (mg/dL)a
All subcohorts 1,194 97–324 195 (33) 174 192 214
INMA-Valencia 479 119–324 201 (33) 180 199 220
INMA-Sabadell 398 105–283 190 (31) 170 188 208
INMA-Gipuzkoa 317 97–321 193 (34) 171 188 211
Triglycerides (mg/dL)a
All subcohorts 1194 35–374 105 (42.8) 76 96 126
INMA-Valencia 479 38–374 111 (45) 81 103 136
INMA-Sabadell 398 35–333 107 (44) 77 96 127
INMA-Gipuzkoa 317 40–250 94 (35) 69 86 112
CRP (mg/dL)b
All subcohorts 651 0.03–6.5 0.6 (0.7) 0.2 0.4 0.7
INMA-Valencia NA NA NA NA NA NA
INMA-Sabadell 329 0.02–6.5 0.7 (0.7) 0.2 0.3 0.6
INMA-Gipuzkoa 322 0.03–5.4 0.6 (0.7) 0.2 0.3 0.6
Note: CRP, C-reactive protein; INMA, Environment and Childhood Project (INfancia y
Medio Ambiente); Max, maximum value; Min, minimum value; NA, not available; P25,
percentile 25; P50, percentile 50; P75, percentile 75; SD, standard deviation.
aData for cholesterol and triglycerides were missing for a total of 46 women from
Valencia (n=28), Sabadell (n=13), and Gipuzkoa (n=5).
bData for CRP were missing for a total of 589 women from Valencia (n=507) and
Sabadell (n=82).
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addition, there was only a weak positive association between
PFHxS and GDM (44 cases), and there was no evidence of posi-
tive associations between either outcome and PFOA or PFOS. In
a study of pregnant Faroese women (49 GDM cases vs. 555
women without GDM), no clear association with GDMwas found
for PFOS, PFOA, PFHxS, PFNA, perﬂuorodecanoic acid
(PFDA), or overall PFAS exposure (Valvi et al. 2017). In the pres-
ent study, associations derived using a multipollutant model that
included all four PFASs were substantially attenuated for PFHxS
and IGT, whereas associations between PFOS and IGT were com-
parable to those found using the single-pollutant models.
Although we found some evidence of a positive association
between PFOS and GDM, our ﬁndings for GDM (including null
ﬁndings for other PFASs) were imprecise owing to the small num-
ber of cases (n=53) and should therefore be interpreted with cau-
tion. In addition, women were evaluated for IGT and GDM at
their physician’s discretion, which may have resulted in some
women being misclassiﬁed as noncases for both outcomes.
Moreover, we did not have information on IGT (without GDM)
for women from the Valencia subcohort, although ORs for associ-
ations between IGT and PFOS and PFHxS when Valencia women
were excluded were generally consistent with those from the pri-
mary analysis.
Studies using animal models have indicated that PFOS and
PFOA may interfere with the phosphatidylinositol 3-kinase-
serine/threonine protein kinase (PI3K-AKT) signaling pathway,
which plays an important role in the metabolic actions of insulin
(Yan et al. 2015). PFOA exposure decreased expression of the PI3-
AKT signaling pathway in rats (Yan et al. 2015), and in vitro
experiments using human hepatoma HepG2 cells suggested that
PFOS exposure may also inhibit AKT activation, leading to insulin
resistance (Qiu et al. 2016). Therefore, the associations of PFOS
and IGT observed in our study could be causal and require further
conﬁrmation in other populations. Such conﬁrmation is critical
because GDM is associated with short- and long-term adverse out-
comes in the mother and in her oﬀspring, including an increased
risk of fetal macrosomia (i.e., high birth weight) and hyperinsulin-
emia, as well as with higher risks of cesarean section and hyperten-
sive disorders in the mother (Kampmann et al. 2015). Moreover,
women diagnosed with GDM are more likely to develop type 2 dia-
betes, metabolic syndrome, and cardiovascular disease after preg-
nancy, and their children are at increased risk of childhood obesity
and glucose intolerance (Kampmann et al. 2015).
A previous cross-sectional study of Norwegian women
(n=891) reported a positive association between PFOS and total
cholesterol and weaker positive associations for all but one of the
other six PFASs evaluated (Starling et al. 2014). PFOS and other
PFASs were also associated with higher HDL cholesterol, a com-
ponent of total cholesterol that is generally considered to be bene-
ﬁcial to health. PFOS and PFOA were also positively associated
with serum total cholesterol levels in late pregnancy (approxi-
mately 30 wk) in a large Danish cohort (n=854) that did not
evaluate associations with HDL or other PFASs (Skuladottir
et al. 2015). In the present study, we measured PFAS exposures
and total cholesterol (but not HDL) at an earlier stage of preg-
nancy (approximately 13 wk), and we found evidence of a weak
positive association between total cholesterol and PFOA,
whereas associations with other PFASs were essentially null.
Diﬀerences in the timing of exposure and outcome measure-
ments and diﬀerences in exposure ranges (which were higher
for PFOS in both previous studies, and for PFOA in the
Danish study, compared with the present study) may have
contributed to inconsistencies among the studies. In addition,
individual PFAS concentrations were moderately to highly cor-
related in all three study populations, which makes it diﬃcult to
attribute associations to speciﬁc individual PFAS compounds. A
variety of noncausal mechanisms may also contribute to, or
explain, inconsistent ﬁndings, including random error, selection
bias, confounding, and diﬀerences in susceptibility related to
coexposures, comorbid conditions, or other factors. We found
evidence of negative associations with triglyceride levels, particu-
larly for PFOS and PFNA, although eﬀect estimates were simi-
lar for all quartiles above the reference level, and they were
attenuated in the multipollutant adjusted model. Starling et al.
(2014) examined seven PFASs and triglycerides in Norwegian
women, but the results did not support clear dose–response rela-
tionships overall [although there were statistically signiﬁcant
associations for the fourth vs. ﬁrst quartile of perﬂuoroundeca-
noic acid (PFUnDA) and the second vs. ﬁrst quartile of perﬂuor-
oheptane sulfonate (PFHpS)]. In an in vitro study, PFASs with
4–12 carbons (including the compounds we studied) activated
the human peroxisome proliferator-activated receptor a (PPARa)
in transiently transfected COS-1 cells (Wolf et al. 2012).
Figure 1. Adjusted odds ratios (ORs) [95% conﬁdence intervals (CIs)] for
the associations between quartile-speciﬁc perﬂuoroalkyl substances (PFAS)-
exposure groups and gestational diabetes mellitus (GDM) (A) and impaired
glucose tolerance (IGT) (B). All models are adjusted for subcohort, country
of birth, prepregnancy body mass index, previous breastfeeding, parity, gesta-
tional week at blood extraction, physical activity, and relative Mediterranean
Diet Score (rMED). See Table 4 for corresponding numeric data. PFHxS, per-
ﬂuorohexane sulfonate; PFNA, perﬂuorononanoate; PFOA, perﬂuoroocta-
noate; PFOS, perﬂuorooctane sulfonate.
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PPARa regulates fatty acid uptake and metabolism, and its activa-
tion may reduce plasma triglycerides and increase HDL cholesterol
levels (Shah et al. 2010). However, additional observational and ex-
perimental studies are needed to conﬁrm associations and to
investigate possible PPAR-dependent or independent mechanisms
for eﬀects of PFASs on lipid metabolism.
It has been proposed that PFAS exposures may aﬀect health
by increasing inﬂammation (Lau et al. 2007), and serum CRP is a
well-established clinical marker of systemic inﬂammation. However,
information on CRP was available for only a subset of the study popu-
lation, and the overall results were imprecise and inconclusive. Larger
studies integrating inﬂammatory markers beyond CRP are needed to
evaluate any potential role of inﬂammation in PFAS-related metabolic
eﬀects.
Compared with INMA participants who were excluded from
the present analysis (because of missing information for PFASs
or the study outcomes), women who were included were more
likely to have been born in Spain, to have higher levels of educa-
tion and social class, and to be older. Included women also had a
higher prevalence of IGT and GDM and somewhat lower triglyc-
eride serum levels and total energy intake. In addition, a previous
analysis of the INMA cohort showed that women born outside
Spain had lower average PFAS concentrations than women born
in Spain (Manzano-Salgado et al. 2016). Therefore, ﬁndings for
the women included in the present analysis may not be represen-
tative of the INMA cohort population overall. Further, cross-
sectional associations between PFAS and total cholesterol and
triglycerides might be explained by reverse causation if, for
example, PFAS pharmacokinetics are aﬀected by lipid levels, or
if PFAS and lipid concentrations are both inﬂuenced by a com-
mon factor. Total cholesterol and triglycerides were measured in
nonfasting samples collected from the pregnant women in our
study population, which may have resulted in values that were
not representative of the usual lipid levels in some women.
Although our study had a number of strengths, we cannot rule
out the potential inﬂuence of random error, bias due to uncon-
trolled confounding, outcome misclassiﬁcation, or other meth-
odological issues that might produce misleading results, and it
will be important for our ﬁndings to be conﬁrmed in additional
study populations. Strengths of this study include the assessment
of PFAS exposures using plasma biomarkers. The long elimina-
tion half-lives of PFOA, PFOS and PFHxS in human blood are
estimated to be from 3 to 9 y (Olsen et al. 2007); thus, one single
PFAS measurement may reﬂect chronic exposure. Moreover, we
measured PFAS concentrations early in pregnancy, which may
reduce the likelihood of confounding due to physiological
changes of gestation, such as changes in the glomerular ﬁltration
rate (Verner et al. 2015). The large sample size and the broad list
of measured confounders are other important strengths of this
study.
Conclusion
Our ﬁndings suggest that PFAS exposures may inﬂuence lipid
metabolism and glucose tolerance during pregnancy. To our
knowledge, this is the largest study of associations between
PFAS exposures and multiple metabolic outcomes in pregnant
women to date. Our ﬁndings require conﬁrmation but are worthy
of further exploration, given their potential implications for the
short- and long-term health of mothers and their children.
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